{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:29:44Z","timestamp":1754144984724,"version":"3.41.2"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,16]]},"DOI":"10.7759\/cureus.88054","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T09:02:01Z","timestamp":1752656521000},"source":"Crossref","is-referenced-by-count":0,"title":["Bullous Pemphigoid Secondary to Dipeptidyl Peptidase-4 (DPP4) Inhibitor: A Case Report"],"prefix":"10.7759","author":[{"given":"Raquel","family":"Rosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Sousa Cardoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00eas","family":"Pinheiro Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Leal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e1rbara","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori L","year":"2022","unstructured":"Borradori L, Van Beek N, Feliciani C, et al.. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2022, 36:1689-704. 10.1111\/jdv.18220","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref2","article-title":"","author":"Baigrie D","year":"2024","unstructured":"Baigrie D, Nookala V. Bullous Pemphigoid. StatPearls [Internet], Treasure Island, FL; 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK535374\/."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2011.03.005","article-title":"Bullous pemphigoid: From the clinic to the bench","volume":"30","author":"Di Zenzo G","year":"2012","unstructured":"Di Zenzo G, Della Torre R, Zambruno G, Borradori L. Bullous pemphigoid: From the clinic to the bench. Clin Dermatol. 2012, 30:3-16. 10.1016\/j.clindermatol.2011.03.005","journal-title":"Clin Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000452828","article-title":"Successful treatment of a bullous pemphigoid patient with rituximab who was refractory to corticosteroid and omalizumab treatments","volume":"9","author":"Bilgi\u00e7 Temel A","year":"2017","unstructured":"Bilgi\u00e7 Temel A, Bassorgun CI, Akman-Karaka\u015f A, Alpsoy E, Uzun S. Successful treatment of a bullous pemphigoid patient with rituximab who was refractory to corticosteroid and omalizumab treatments. Case Rep Dermatol. 2017, 9:38-44. 10.1159\/000452828","journal-title":"Case Rep Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3391","article-title":"Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: A systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Yang W","year":"2021","unstructured":"Yang W, Cai X, Zhang S, Han X, Ji L. Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: A systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2021, 37:e3391. 10.1002\/dmrr.3391","journal-title":"Diabetes Metab Res Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02272-x","article-title":"Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: A meta-analysis of randomized controlled trials","volume":"69","author":"Silverii GA","year":"2020","unstructured":"Silverii GA, Dicembrini I, Nreu B, Montereggi C, Mannucci E, Monami M. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: A meta-analysis of randomized controlled trials. Endocrine. 2020, 69:504-7. 10.1007\/s12020-020-02272-x","journal-title":"Endocrine"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1587","article-title":"Association between medication use and bullous pemphigoid: A systematic review and meta-analysis","volume":"156","author":"Liu SD","year":"2020","unstructured":"Liu SD, Chen WT, Chi CC. Association between medication use and bullous pemphigoid: A systematic review and meta-analysis. JAMA Dermatol. 2020, 156:891-900. 10.1001\/jamadermatol.2020.1587","journal-title":"JAMA Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/383982-bullous-pemphigoid-secondary-to-dipeptidyl-peptidase-4-dpp4-inhibitor-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T09:02:01Z","timestamp":1752656521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/383982-bullous-pemphigoid-secondary-to-dipeptidyl-peptidase-4-dpp4-inhibitor-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.88054","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,16]]}}}